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Identification of poor and rapid metabolizers for the category of drugs metabolized by cytochrome P450 2B6
(CYP2B6) is important for understanding the differences in clinical responses of drugs metabolized by this enzyme.
This study reports the prevalence of poor and rapid metabolizers in North Indian population residing in the
National Capital Territory.
The prevalence of poor and rapid metabolizers was determined in the target population for the category of drugs
metabolized by CYP2B6 by measuring plasma bupropion, a drug metabolized by CYP2B6, and its metabolite.
Bupropion (75 mg) was administered to 107 volunteers, and the drug (bupropion) and its metabolite
(hydroxybupropion) were determined simultaneously by LCMS/MS in the plasma. CYP2B6 activity was measured as
hydroxybupropion/bupropion ratio, and volunteers were categorized as rapid or poor metabolizers on the basis of
cutoff value of log (hydroxybupropion/bupropion). Significant differences were observed between the mean
metabolite/drug ratio of rapid metabolizers (Mean = 0.59) and poor metabolizers (Mean = 0.26) with p<0.0001.
Results indicate that 20.56% individuals in the target population were poor metabolizers for the category of drugs
metabolized by CYP2B6. Cutoff value defined in this study can be used as a tool for evaluating the status of CYP2B6
using bupropion as a probe drug. The baseline information would be clinically useful before administering the
drugs metabolized by this isoform.
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Human cytochrome P450 2B6 (CYP2B6) is involved in
the biotransformation of a variety of clinically important
drugs such as the antiretroviral nevirapine (NVP) and
efavirenz (EFV), which are used to treat AIDS and/or
stop the spread of HIV infection (Erickson et al. 1999;
Ward et al. 2003), antimalarial drug artemisinin
(Simonsson et al. 2003; Mehlotra et al. 2006) and other
drugs including cyclophosphamide, tamoxifen, diazepam,
and bupropion (Lang et al. 2001; Wang and Thompkins
2008). However, the rates with which these drugs are
metabolized vary considerably in individual hepatic* Correspondence: sali@jamiahamdard.ac.in
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in any medium, provided the original work is pmicrosomes, and this variation is believed to be caused
by CYP2B6 isoforms, besides the environmental factors
such as the enzyme inducers. Clinical importance of
genetic variations and role of ethnicity of CYP2D6,
CYP2C19, CYP2C9, and CYP2D6 are well known
(Adithan et al. 2003; Anitha and Banerjee 2003; Kumar
et al. 2010; Lamba et al. 1998a, b) but CYP2B6 has only
recently been recognized to code for a highly variable
enzyme of potential clinical importance (Lang et al.
2001; Lamba et al. 2003). More than 100 DNA variations
have been reported in CYP2B6 gene, and many of them
show extensive linkage disequilibrium giving rise to dis-
tinct haplotypes. The spectrum of functional conse-
quences of these variations is wide and includes null
alleles with no detectable function and/or expression
(alleles CYP2B6*8, *12, *15, *18, *21), alleles withs an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Number of volunteers rejected on the basis of
medical and clinical examination




Outliers in hemogram and
biochemical parameters
11
Drug of Abuse positive 18
Serology positive (HIV, HCV, HbsAg) 6
Others 12
Total (Rejected) 63
Selected for phenotyping (Total - Rejected) 170–63 = 107
A total number of 170 volunteers were screened and 107 were recruited for the
study.
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*11, *14, *19, *20, *21) (Lamba et al. 2003; Klein) and
alleles with increased expression (CYP2B6*22) (Zukunft
et al. 2005).
Clinical relevance of CYP2B6 variation has been
demonstrated for the anti-HIV drug efavirenz. Common
clinical practice of administering the same dose to all
patients leads to profound differences in drug plasma
concentration, which is correlated with patient genotype
(Tsuchiya et al. 2004; Novoa et al. 2005). Patients with
high drug concentrations are at risk of developing con-
centration related central nervous system toxicity, in-
cluding insomnia, fatigue, and headache, which often
lead to discontinuation of therapy. Thus, for a drug such
as efavirenz, dose adjustment based on CYP2B6 geno-
type could prevent administration of too-high doses, and
increase the safety and efficacy of therapy. Further,
CYP2B6 variant genotyping at baseline may allow clini-
cians to identify patients who are at risk of treatment
failure or drug toxicity (Novoa et al. 2005; Ramachan-
dran et al. 2009). Some of these variations are rare, but
many are common, with allele frequencies between 10%
and almost 50%, depending on the population (Klein
et al. 2005; Solus et al. 2004). Ethnic or racial inter-
individual CYP2B6 polymorphism in various populations
has been reported in Caucasians (Lang et al. 2001), Japa-
nese (Hiratsuka et al. 2002 and Hiratsuka et al. 2004),
African-American-Hispanic (Lamba et al. 2003; Hesse
et al. 2004), Korean (Cho et al. 2004), Mongolian
(Davalkham et al. 2009), Spain (Novoa et al. 2005), and
South Indians (Ramachandran et al. 2009), but not in
North Indian population, and, hence, CYP2B6 was
selected in this study.
Aim of the study
This study was aimed at to find out the prevalence of
poor and rapid metabolizers for the category of drugs
metabolized by CYP2B6 in the target population by
measuring plasma bupropion, a drug metabolized by
CYP2B6, and its metabolite.
Method
Clinical study
Study protocol and corresponding informed consent
form (ICF) were reviewed by the Institutional Review
Board, and procedures were in accordance with the Hel-
sinki Declaration of 1975, as revised in 2000. Subjects
were informed before initiation of the study through an
oral presentation regarding the purpose of the study,
procedures to be carried out, potential hazards and
rights of the subjects. Subjects (170) were selected ran-
domly from the volunteer bank of clinical pharmacology
unit of Ranbaxy Laboratories Limited. The volunteer
bank comprises of healthy volunteers from the IndianNational Capital Region (INCR), which includes the
metropolitan area encompassing the entire national cap-
ital territory (Delhi) and urban areas of neighboring
states of Haryana, Uttar Pradesh and Rajasthan. Subjects
were selected on the basis of inclusion and exclusion cri-
teria after obtaining written informed consent. Medical
histories and demographic data were recorded. Each
subject underwent physical examination and laboratory
tests of hematology, hepatic and renal function.
Hematological parameters were analyzed on fully auto-
mated five part differential count autoanalyzer, Sysmex
XT 1800xi, procured from Transasia Co. The biochem-
ical parameters, which included plasma glucose, serum
blood urea nitrogen, serum creatinine, serum total bili-
rubin, serum alkaline phosphatase, serum alanine and
aspartate aminotransferases, serum cholesterol, and
urine drug of abuse, were analyzed on a fully automated
biochemistry analyzer, Dimension Rxl (Seimens Diagnos-
tics, USA), according to manufacturer’s instruction.
Urinalysis, routine and microscopic examination, was
done by manual dipstick method (Multistick from Sei-
mens Diagnostics). Rejection or selection of subjects was
based on specific clinical and medical examination as
shown in Table 1. Subjects were kept under medical
supervision in the clinical pharmacology unit of Ranbaxy
Laboratories Limited, New Delhi. Bupropion (Wellbu-
trinR, GlaxoSmithKline, USA) (75 mg) was administered
orally to selected (107) volunteers along with 240 ml of
water under the supervision of a trained Medical Officer.
The EDTA blood sample (6 ml each) was collected at 0,
1, 3, 6 and 10 h after drug administration. Number of
volunteers was calculated statistically based on the
prevalence of percentage poor metabolizers present
worldwide. Sample size of 100 volunteers was calculated
statistically. The prevalence of CYP2B6 in Indian popu-
lation is ~40%, and therefore, a sample size of 100 sub-
jects was calculated and found sufficient to estimate the
prevalence with expected 95% binomial confidence
Varshney et al. SpringerPlus 2012, 1:34 Page 3 of 7
http://www.springerplus.com/content/1/1/34interval ranging 30 to 50%. Based on the simulation with
higher sample size (200 or 300), not much benefit was
found in precision with a sample size of 100 subjects.
Determination of bupropion and its metabolite by
LCMS/MS
CYP2B6 activity was determined by calculating hydroxy-
bupropion/bupropion ratio in plasma by LCMC/MS on
Waters Quattro premier mass spectrometer. Samples
were analyzed using a set of calibration standards spiked
in human plasma. Three levels of quality control sam-
ples were distributed through each batch of study sam-
ples assayed to monitor the performance of testing.
Experiments were carried out by liquid-liquid extraction
with ethyl acetate selected as an optimum extraction
solvent for the estimation of both bupropion and its me-
tabolite. Briefly, 100 μl of 0.5N sodium carbonate was
added to 100 μl of plasma and 50 μl of internal standard
dilution (5 μg/ml diazepam solution) in a clean test tube.
Sodium carbonate was added to the extraction buffer to
maintain the drug and metabolite in un-ioned state. The
mixture was vortexed for a minute, and 4 ml extraction
solution (ethyl acetate) was added to it followed by cen-
trifugation at 4,000 rpm for 5 minutes. The organic layer
(3.5 ml) was removed and transferred to a fresh tube
and mixed with 50 μl of 0.1N HCl. Supernatant was vor-
texed for 10 seconds and kept in an evaporator under
nitrogen at 50°C for 10 minutes, and then reconstituted
in 250 μl diluent consisting of 80 parts of water and 20
parts of acetonitrile. Reconstituted solution was injected
into LCMS for bupropion and hydroxy bupropion esti-
mation. Six replicates of aqueous dilutions of bupropion,
hydroxybupropion, and diazepam were injected and
their peak response ratios were recorded to check the
interferences or specificity. The calibration ranges for
bupropion (1–500 ng/ml) and hydroxybupropion (5–
2500 ng/ml) were selected. Calibration curve was
accepted if the back-calculated concentrations of mini-
mum 75% of calibration standard (without including
standard zero) were within 85% and 115% of the nom-
inal concentration. Coefficient of correlation of linear re-
gression (r2) of calibration curve was 0.98. Six different
batches of biological matrix (9204, 122412, 123892,
123852, 123202 and 122501) were analyzed for selectiv-
ity exercise. Six blank samples spiked with LLOQ (lower
limit of quantification) were processed by sample prep-
aration procedure. Peak area was evaluated at the reten-
tion time of analyte and internal standard. Selectivity
was accepted only if the peak area in blank at retention
time of analyte was <20% of mean peak area of analyte
at LLOQ and <5% of mean peak of internal standard in
calibration standard for internal standard. Long-term
stability of analyte was evaluated using low and high QC
samples stored below −50°C in deep freezer for a periodof 15 days. Six replicates of low and high quality control
samples were used for each stability exercise. The stored
QC samples were analyzed against freshly spiked calibra-
tion curve.
Data analysis
The population was categorized as poor and rapid meta-
bolizers for the group of drugs metabolized by CYP2B6
on the basis of CYP2B6 activity. The enzyme activity
was determined by evaluating hydroxybupropion/
bupropion ratio. The concentration of bupropion and
hydroxybupropion was quantified from the blood sam-
ples drawn at pre-dose, 1 h post-dose, 3 h post-dose, 6 h
post-dose and 10 h post-dose from the subjects kept in-
house till 10 h post-dose. Based on the concentration of
the parent drug at the above mentioned time points,
tmax (time to reach the drug at the highest concentra-
tion) of 3 h was selected for the evaluation of CYP2B6
activity. The frequency histogram was constructed with
log (metabolite/drug at tmax) versus the number of
volunteers. The presence of different categories of indivi-
duals was indicated in frequency histogram if the fre-
quency histogram was different from the normal
distribution. On visual inspection of frequency histo-
gram, approximate antimode position was established as
the point on graph where two different modes are sepa-
rated. However the exact antimode was derived by pro-
bit plot analysis. This is a graphical method in which
standard deviates of a normal distribution are plotted
against the log (metabolite/drug). Deviations from lin-
earity in probit plots have been interpreted as existence
of polymorphism. Scatter type chart was prepared with
log (metabolite/drug) on x-scale and probit on y-scale.
Trendlines were added to the plot to get best linear fit.
Based on the selected trendline, a polynomial equation
of regression was obtained. Intercept at x was the anti-
mode. Individuals having log metabolite/drug ratio less
than the antimode were classified as poor metabolizers.
The mean of the ratio (metabolite/drug) of poor and
rapid metabolizers was analyzed by student t-test to
evaluate the significance of difference between poor and
rapid metabolizers and the P value of less than 0.05 was
accepted as statistically significant.
Results
None of the volunteers reported any undesirable effect
or adverse event during or after the study. No interfer-
ence was observed in the retention time of bupropion or
hydroxybupropion. The retention time of 1.16 (bupro-
pion), 1.13 (hydroxybupropion), and 1.70 min (diaze-
pam) was tuned. The sensitivity of estimation of
bupropion and hydroxybupropion or percent coefficient
variation at LLOQ was 6.59% and 6.87%, respectively.
The estimation procedure was specific as no interfering
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matrix. The coefficient of correlation of linear regression
(r) was 0.9982 for bupropion and 0.9982 for hydroxybu-
propion. Calibration curves of bupropion and hydroxy-
bupropion are shown in Figure 1. Percent accuracy of
the calibrators and quality control samples was between
85 and 115%. Precision for bupropion and hydroxybu-
propion was estimated as mean %CV (coefficient of vari-
ation). It was between 3.9 and 5.7% for all three levels of
quality control samples. The values were within FDA
defined limit of <15%. The frequency histogram and pro-
bit plot analysis described the bimodality of the studied
population with respect to log (metabolite/drug ratio)
(Figures 2 and 3). Regression analysis done on the probit
plot yielded a best linear fit at R2 = 0.938. The trendline
equation (y = −3.318x2 + 3.747x + 1.429) was obtained.
On solving the equation, intercept at x-axis, which was
actually an antimode, was found to be 0.5 [log (hydroxy-
bupropion/bupropion)]. Individuals having log ratio of
hydroxybupropion/bupropion <0.5 were categorized as
poor metabolizers. Based on the antimode value, 20.56%
of population was categorized as poor metabolizer for
the category of drugs metabolized by CYP2B6. Signifi-
cant difference was observed between the mean ratio of































































Figure 1 Calibration curves for the estimation of (a) bupropion, and (and poor metabolizers (Mean = 0.26) with P<0.0001
using student t-test (Table 2).
Discussion
This study reports the prevalence of poor and rapid
metabolizers for the category of drugs metabolized by
CYP2B6 in the target population. Interest in CYP2B6
has been developed by an ever-increasing list of sub-
strates metabolized by this isoform as well as poly-
morphic and ethnic variations in the expression and
activity of CYP2B6. Previous in vitro heterologous ex-
pression studies have shown that the polymorphism
found in alleles CYP2B6*5, *6, *7, and *9 can alter the
expression and/or activity of the enzyme (Ariyoshi et al.
2001; Iwasaki et al. 2004; Jinno et al. 2003). The func-
tional significance of CYP2B6 variants has been shown
for a variety of drugs. For example, in AIDS clinical
studies, CYP2B6 variants have been associated with 2-
to 4-fold higher plasma EFV and NVP (Haas et al. 2004;
Rotger et al. 2005; Rodriguez-Novoa et al. 2005; Tsu-
chiya et al. 2004) in HIV patients; ≥2-fold higher plasma
EFV concentration is associated with neuropsychological
adverse effects (Haas et al. 2004; Rotger et al. 2005;
Marzolini et al. 2001; Hasse et al. 2005). Besides the
antiretroviral drugs, CYP2B6 variants have also beenurve bupropion 
hting):y=0.0076x+0.00086(r=0.9982) 

























Figure 2 Frequency histogram plotted as log ratio of hydroxybupropion/bupropion vs. number of individuals. Arrow indicates antimode
at 0.5.
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of bupropion (an antidepressant) (Hesse et al. 2004) and
cyclophosphamide (an anticancer and immunosuppres-
sive) (Xie et al. 2003). This study is the first attempt to
identify poor and rapid metabolizers of the drugs meta-
bolized by CYP2B6 in north Indian population residing
in the national capital. Bupropion is widely used in phe-
notyping of CYP2B6 (Faucette et al. 2000; Kirchheiner
et al. 2003; Rotger et al. 2007; Chung et al. 2011) and
has been found to be a safe and tolerable drug. We did
not report adverse effect of the drug during the clinical
trial, and found it a safe, suitable and tolerable drug. Bu-
propion and its metabolites were measured in the
plasma by LCMS/MS. Validation parameters were within
the acceptable limits as recommended in FDA. Analysis
of the results based on frequency histogram and probit
analysis revealed that 20.56% of the target population
was poor metabolizer. The prevalence of poor metaboli-














Figure 3 Probit plot of log (hydroxybupropion/bupropion) vs. probit.lower than West Africa (54%) (Malhotra et al. 2006),
Papua New Guinea (63%) (Malhotra et al. 2006), Spain
(40%) (Novoa et al. 2005), Mongolian (35.5%) (Davalk-
ham et al. 2009), Japanese (32.6%) (Gatanaga et al.
2007), Han Chinese (32.9%) (Guan et al. 2006), African
American (54.6%) (Klein et al. 2005), Ghanians (59.7%)
(Klein et al. 2005), Caucasians (38.9%) (Blievernicht et al.
2007) and Koreans (23.9%) (Klein et al. 2005). In India,
percentage of poor metabolizers was 40% in South In-
dian population (Ramachandran et al. 2009). In compari-
son, North Indian population reported 20.56% poor
metabolizers, which is considerably lower. The differ-
ence might be attributed to the life style and genetics of
these two diverse groups of populations in India. In a
study by Rendic (2002), nutrition has been reported to
play an important role in drug metabolism and affect
some of the CYP isoforms including 1A1, 1A2, 1B1,
2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4 and 3A5. Similarly,




Table 2 Evaluation of mean ratio of poor and rapid










Degree of freedom 76 -
t Statistics −15.2236 -
P (T<=t) one-tail 4.34E-25 -
t Critical one-tail 1.665151 -
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2001). In this study, we could not evaluate the correl-
ation of phenotype with genotype, which would be ad-
vantageous to understand the genetic background of the
difference in poor and rapid metabolizers. However, the
prevalence of 20.56% of poor phenotype for CYP2B6
reported in this study cannot be ignored because of its
involvement in the metabolism of drugs commonly used
for the treatment of cancer, HIV infection and depres-
sion, where the treatment is usually long term, and these
drugs may be toxic due to poor metabolism.
Conclusion
The antimode or cutoff defined in this study can be used
as a tool for evaluating the status of CYP2B6 activity
using bupropion as a probe drug. The baseline informa-
tion would be clinically useful before administering the
drugs metabolized by this isoform.
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